Shots: The US FDA’s approval is based on four clinical studies (ACHIEVE I, ACHIEVE II, UBR-MD-04 and 3110-105-002), which demonstrated efficacy, safety and tolerability of Ubrelvy (50, 100mg) for the […]readmore
Tags : Ubrogepant
Shots: The NDA filing is based on P-III ACHIEVE I (50 mg/100 mg) & ACHIEVE II (25mg/50mg) + two additional safety studies (UBR-MD-04 & 3110-105-002) assessing Ubrogepant vs PBO in […]readmore
Shots: The two pivotal study conducted for assessing ubrogepant (50/100) vs usual care & ubrogepant (100) vs PBO for 1year & 8 wks. respectively to treat migrane in adults, evaluating […]readmore